Physician profile
Hani Sabahi
NPI 1710299847
$19,360.56
in general payments reported to CMS, 2019-2025
36 companies · $2,971 in 2025
The $2,971 reported for 2025 was more than what 87% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $941 · 2020: $1,131 · 2021: $2,162 · 2022: $2,141 · 2023: $7,356 · 2024: $2,659 · 2025: $2,971.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,886 · Consulting Fee: $5,100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,886.47 |
| Consulting Fee | $5,100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $5,100.00 | 2023 | |
| Abbvie INC. | $3,174.34 | 2019-2025 | Rinvoq, Viberzi, Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,210.03 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $1,105.60 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $958.28 | 2019-2025 | Tremfya, Stelara |
| Qol Medical, LLC | $824.03 | 2020-2025 | Sucraid, Sucraid |
| E.R. Squibb & Sons, L.L.C. | $712.65 | 2021-2024 | Zeposia |
| Celgene Corporation | $663.81 | 2021-2024 | Zeposia |
| Ferring Pharmaceuticals INC. | $559.72 | 2019-2024 | Rebyota |
| Genzyme Corporation | $524.21 | 2022-2025 | |
| Pfizer INC. | $448.00 | 2019-2025 | |
| Madrigal Pharmaceuticals | $413.95 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $301.92 | 2022-2025 | Dupixent |
| Gilead Sciences, INC. | $271.07 | 2021-2025 | |
| Nestle Healthcare Nutrition INC. | $231.71 | 2021-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $229.34 | 2024-2025 | Vegzelma, Zymfentra |
| Phathom Pharmaceuticals, INC. | $173.83 | 2024 | Voquezna |
| Boston Scientific Corporation | $156.29 | 2021-2022 | |
| Noah Medical Corporation | $151.68 | 2025 | Galaxy |
| Janssen Scientific Affairs, LLC | $151.60 | 2021-2022 | |
| Alfasigma USA, INC. | $117.67 | 2020 | |
| Lilly USA, LLC | $117.65 | 2024-2025 | Omvoh |
| Ardelyx, INC. | $115.97 | 2024-2025 | Ibsrela |
| Ethicon US, LLC | $112.64 | 2025 | Linx Reflux Management System, Harmonic |
| Aimmune Therapeutics, INC. | $73.51 | 2025 | Zenpep, Vowst |
| Novo Nordisk INC | $73.37 | 2025 | Wegovy |
| Braintree Laboratories, INC. | $72.83 | 2020-2022 | |
| Intercept Pharmaceuticals, INC. | $65.65 | 2020-2024 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $64.92 | 2024 | Iqirvo |
| Shionogi INC | $63.47 | 2019 | |
| Ironwood Pharmaceuticals, INC | $31.96 | 2020-2024 | |
| Endogastric Solutions, INC | $27.01 | 2019 | |
| Conmed Corporation | $21.20 | 2024 | Conmed Dilation, Conmed Polypectomy |
| Pharmacosmos Therapeutics INC. | $14.61 | 2020 | |
| Allergan, INC. | $13.26 | 2019 | |
| W. L. Gore & Associates, INC. | $12.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hani Sabahi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.